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CD161 is a C-type lectin-like receptor expressed on the majority of natural killer (NK) cells; 
however, the significance of CD161 expression on NK cells has not been comprehensively 
investigated. Recently, we found that CD161 expression identifies a transcriptional and 
innate functional phenotype that is shared across various T cell populations. Using mass 
cytometry and microarray experiments, we demonstrate that this functional phenotype 
extends to NK cells. CD161 marks NK cells that have retained the ability to respond to 
innate cytokines during their differentiation, and is lost upon cytomegalovirus-induced 
maturation in both healthy and human immunodeficiency virus (HIV)-infected patients. 
These pro-inflammatory NK cells are present in the inflamed lamina propria where they 
are enriched for integrin CD103 expression. Thus, CD161 expression identifies NK cells 
that may contribute to inflammatory disease pathogenesis and correlates with an innate 
responsiveness to cytokines in both T and NK cells.
Keywords: natural killer cells, cD161, pro-inflammatory cytokines, cytomegalovirus, human immunodeficiency 
virus, inflammatory bowel diseases
inTrODUcTiOn
Natural killer (NK) cells are the most classical population of innate lymphoid cells, expressing a 
heterogeneous repertoire of germline-encoded receptors that allows them to distinguish infected or 
stressed cells from healthy cells (1). CD161 is one of the earliest markers expressed during NK cell 
maturation from CD34+ hematopoietic stem cell precursors (2). Expression of CD161 correlates with 
the cytotoxic function of CD16+ NK cells (3), and ligation of CD161 with its ligand LLT1 inhibits 
NK cell cytotoxicity and cytokine secretion (4, 5).
CD161 is expressed early in NK cell development, where it may facilitate cross-talk of NK cell 
precursors with cells within the bone marrow, and is involved in CXCL8 release (6–8). Within the 
periphery, cross-linking of CD161 leads to an increase in IFNγ expression and inhibition of NK cell 
cytotoxicity (4, 5, 9, 10).
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There have been various reports of modulated expression of 
CD161 on NK cells during viral infections. For instance, reduced 
CD161 expression in acute hepatitis C virus (HCV) infection 
predicted viral clearance (11), and correlated with increased 
liver inflammation in chronic HCV infection (12). Patients with 
chronic human immunodeficiency virus (HIV) infection have 
depleted CD161+ NK cells compared to healthy donors (13, 14). 
Recently, a population of NK cells with memory-like properties 
has been described in the context of cytomegalovirus (CMV) (15, 
16), referred to as “adaptive” NK cells (17). This subset expands in 
recipients of solid organ (18) or umbilical cord blood transplanta-
tion (19) during primary CMV infection or reactivation. These 
cells are commonly NKG2C+ and CD57++ (18, 20, 21), and CD161 
expression on these cells has been shown to be reduced (17, 20). 
Overall, despite reports on the expression of CD161 in different 
viral infections, our understanding of its significance—i.e., the 
function of NK cells based on CD161 expression—is incomplete.
Pro-inflammatory cytokines strongly influence the activation 
of NK cells against viral infections, promoting their cytotoxicity, 
expansion, and production of immunomodulatory cytokines. 
IL-12 and IL-18, for example, induce IFNγ production from 
NK  cells which is critical for NK  cell-mediated protection in 
murine CMV (MCMV)-infected livers (22) and is required for the 
primary expansion of memory NK cell responses against MCMV 
infection (23, 24). Recently, we have demonstrated that CD161-
expressing T cells share a transcriptional signature, regardless of 
T cell receptor (TCR) expression (25), which is associated with 
an increased responsiveness to IL-12 and IL-18. Whether this 
transcriptional signature and functional correlation with CD161 
holds true within NK cells is unknown.
Using flow and mass cytometry, we show in this study that 
CD161 expression marks pro-inflammatory NK cells with high 
cytokine responsiveness, independent of CMV status or CD57 
expression. These cells share a transcriptional signature with 
CD161+CD8+T  cells and express the integrin CD103 in the 
inflamed gut of inflammatory bowel disease (IBD) patients. 
Furthermore, we find that CD161 expression is lost from NK cells 
in a CMV-dependent manner from chronic HIV patients from 
the Swiss HIV cohort study (SHCS), which partially recovers with 
anti-retroviral therapy (ART). Overall, these data define the func-
tional correlates of CD161 expression, which can be modulated 
by infection and inflammation.
MaTerials anD MeThODs
cells
Peripheral blood mononuclear cells (PBMCs) were obtained from 
adults (whole blood leukocyte cones, NHS Blood and Transplant 
or laboratory volunteers, numbers varied for individual experi-
ments and are indicated in each figure), 24-month-old donors 
(prospective birth cohort (26), n  =  28) and umbilical cord 
blood samples (Stem Cell Services, NHS Blood and Transplant, 
n =  5). Intestinal lamina propria cells were isolated following 
EDTA washes by Percoll gradient centrifugation (n =  7; Table 
S1 in Supplementary Material). Where indicated, PBMCs were 
obtained from a cohort of treatment-naïve patients from the 
SHCS(n = 27), sampled prior to, and 1 year and 2 years into ART 
(Table S2 in Supplementary Material).
Adult and cord blood samples were collected after ethical 
approval by the Central Office for Research Ethics Committees 
(COREC, local research ethics committee Oxford), reference 
number COREC 04.OXA.010. The NHS Research Ethics System 
provided ethical approval for the Oxford IBD Cohort study (ref-
erence numbers 09/H0606/5 for IBD patients and 11/YH/0020 
and 16/YH/0247 for controls). All patients from the studies above 
provided their informed written consent. The collection of blood 
samples for the 24-month-old study cohort was approved by 
the Human Ethics Committee at Huddinge University Hospital, 
Stockholm, reference code 75/97, 331/02, and the parents pro-
vided their informed verbal consent. No written documentation 
of the participants informed approval was required, which was 
agreed to by the Human Ethics Committee and was according to 
the regulations at the time of the initiation of the study.
The SHCS was approved by the local ethical committees of 
the participating centers: Kantonale Ethikkommission Zürich 
(KEK-ZH-NR: EK-793); Ethikkommission beider Basel (“Die 
Ethikkommission beider Basel hat die Dokumente zur Studie 
zustimmend zur Kenntnis genommen und genehmigt.”); Kantonale 
Ethikkommission Bern (21/88); Comité departmental d’éthique 
des specialités médicales es de médecine communautarie et de 
premier recours, Hôpitaux Universitaires de Genève (01–142); 
Commission cantonale d’éthique de la recherche sur l’être 
humain, Canton de Vaud (131/01); Comitato etico cantonale, 
Repubblica e Cantone Ticino (CE 813); Ethikkommission des 
Kantons St. Gallen (EKSG 12/003), and written informed consent 
was obtained from all participants.
Flow cytometry
Antibodies used were as follows: CD56 BV421, CD3 PE-Cy7 or 
APC-Cy7, CD14 APC-Cy7, CD19 APC-Cy7, CD57 Pacific Blue 
or FITC, CD62L PE-Cy7, CD107a PE-Cy7, CD244 PE-Cy5.5, 
Perforin Pacific blue, CD160 Alexa Fluor 647 (Biolegend), CD16 
eFluor450 or FITC, CD69 FITC, CD94 FITC, CD8a PerCP-Cy5.5 
(eBioscience), CD161 PE or APC, CD56 APC, IFNγ FITC, NKp30 
APC, NKp46 APC, NKp80 APC (Miltenyi Biotec), CD3 Pacific 
Orange, CD4 Qdot 605, Granzyme B APC (Invitrogen), NKG2C 
Alexa Fluor 488 or PE, NKG2D PE, PLZF APC, Granzyme A 
FITC (R&D Systems), CD56 FITC or PE-Cy7, CD85j FITC, 
IFNγ Alexa Fluor 700, Ki67 FITC (BD Biosciences), Granzyme 
K FITC (Immunotools), NKG2A PE, NKp44 PE, CD158e1/
e2 PE (Beckman Coulter), Phosphatidylserine Alexa Fluor 488 
(Merck Milipore). The viability dye Live/Dead fixable Near-IR 
(Invitrogen) was used in all experiments. Anti-KLRG1 FITC was 
kindly provided by H. Pircher. Data were acquired on LSRII (BD 
Biosciences) and analyzed using FlowJo (Treestar, Inc.).
In Vitro assays
Peripheral blood mononuclear cells were cultured for 20 h with 
50  ng/ml IL-12 and IL-18 (Miltenyi Biotec) and Brefeldin A 
(eBioscience) added for the last 4 h. To determine CMV status in 
healthy donors of unknown CMV status, PBMCs were cultured 
with CMV lysate for 16 h at 5 µg/ml (Virusys Corporation), with 
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Brefeldin A (eBioscience) added after 1 h of stimulation, followed 
by analysis of IFNγ secretion. CMV+ donors were defined as 
individuals with IFNγ+CD4+T  cells in response to CMV-lysate 
above background (average % IFNγ+CD4+ T  cells =  0.02% in 
CMV− vs. 2.42% in CMV+ donors). In addition, healthy labora-
tory donors with known CMV seropositivity were included as 
CMV+ donors.
Alternatively, PBMCs or purified CD161+ or CD161− NK cells 
(sorted on a MoFlo, Beckman Coulter) were labeled with 5 µM 
CellTrace Violet (CTV; Invitrogen) according to the manufacturer’s 
protocol and cultured with: IL-2 (100 IU/ml; Roche Diagnostics), 
IL-15 (25  ng/ml; Miltenyi Biotec), Phytohemagglutinin (PHA; 
2 µg/ml, Sigma Aldrich), IL-18 or IL-12 (both 50 ng/ml; Miltenyi 
Biotec), or combinations of stimuli for 6 days. Where indicated cells 
were stained with phosphatidylserine AlexaFluor488 (Millipore) 
following proliferation. Alternatively, CTV-labeled PBMCs were 
cultured on flat bottom ELISA plates (Greiner Bio-One Limited) 
coated with purified anti-CD16 (BD Biosciences), anti-NKG2C 
(R&D Systems), or isotype control (BD Biosciences).
Microarray analysis
CD161+CD161+ or CD161− NK  cells (singlet, alive, CD14−C
D19−CD3−CD56+) were sorted using a MoFlo MLS cell sorter 
(Beckman Coulter) from four donors. Purity was >96%. Three 
out of four donors were CMV seronegative, while the seropositiv-
ity of the remaining donor is unknown. Cell pellets were snap 
frozen and sent to Miltenyi Biotec Genomic Services (Bergisch 
Gladbach) for RNA extraction and hybridization to Agilent 
Whole Human Genome Oligo Microarray. Raw microarray 
image files were processed using Agilent feature extraction, 
and differential gene expression was analyzed using the 
Rosetta Resolver gene expression data analysis system (Rosetta 
Biosoftware). Hierarchical clustering of differentially regulated 
genes (>2-fold, p < 0.01) was completed using the heatmap func-
tion in GENE-E (Broad Institute). The NCBI Gene Expression 
Omnibus accession number for the microarray data reported 
in this paper is GSE98702. The NK cell data were compared to 
genes significantly upregulated (>2-fold, p < 0.05) in a previously 
published dataset of CD161intermediate(int) CD8+ T cells compared to 
the CD161−CD8+T cells (25, 27, 28) using gene set enrichment 
analysis (GSEA) v2.1.0 (29).
Mass cytometry
Frozen PBMCs were thawed and washed in RPMI 1640 with 10% 
fetal calf serum (FCS), supplemented with penicillin/streptomy-
cin and l-glutamine (R10) with DNAse (all from Sigma Aldrich). 
PBMCs were depleted of CD4+T cells, monocytes, and B cells, 
using anti-Mouse IgG Microbeads (Miltenyi Biotec) following 
staining with anti-CD4, or anti-CD33+anti-CD13, or anti-CD20 
antibodies, respectively. Cells were cultured in RPMI 10% FCS 
for 20 h with IL-12 and IL-18 (both 50 ng/ml, Miltenyi Biotec), 
and 1X Brefeldin A (eBioscience) was added at 3 µg/ml for the 
last 4 h. Cells were first stained with the viability marker Cisplatin 
(Sigma Aldrich) at 5 µM in PBS for 5 min on ice, then with metal-
conjugated surface antibodies and fluorochrome-conjugated 
antibodies, in RPMI+10% FCS at 37°C for 15 min. After washing, 
cells were stained in 1% bovine serum albumin/PBS buffer with 
the remaining surface antibodies, including secondary antibodies 
against the fluorescent tags, at 4°C for 15 min. Cells were then fixed 
in Fixation/Permeabilization buffer (eBioscience) for 30 min at 
4°C. Following washing in Permeabilization buffer (eBioscience), 
cells were incubated with intracellular antibodies during 30 min 
at 4°C in Permeabilization buffer. A unique dual combination of 
metal barcodes was added to each sample for barcoding as previ-
ously described (30, 31) and cells were DNA labeled with 250 nM 
iridium interchelator in 2% PFA (DVS Sciences). Cells were fixed 
in 2% PFA overnight at 4°C. Cells were washed twice before dilu-
tion to 5 × 105 cells/ml in distilled water before being acquired on 
a CyTOFTM-2 instrument (Fluidigm). Gating strategy is shown in 
Figure S1 in Supplementary Material. Details of antibodies used 
are shown in Table S3 in Supplementary Material.
t-Distributed stochastic neighbor embedding (t-SNE) analysis 
was either performed in Cytobank (www.cytobank.org; Cytobank 
Inc.) or in R. Biaxial gating was performed on FlowJo Version 10 
software (Treestar).
Fetal calf serum files were imported into R via the read.FCS 
function in the flowCore package, as described previously (31). 
t-SNE analysis was performed using custom R scripts using R 
packages that perform the Barnes-Hut implementation of t-SNE. 
Cells from each cluster identified by t-SNE were grouped and the 
median intensity values for each cluster for every marker was 
calculated for the generation of heatmaps. For Cytobank analysis, 
live, CD45+CD14−CD19−FcεR1−CD123−CD11c− cells were gated 
(excluding monocytes, myeloid and plasmacytoid DC, mast/baso-
phils, and B cells), and t-SNE analysis was performed based on 
the remaining parameters with proportional sampling, so that the 
algorithm samples from gated populations preserving their rela-
tive abundance. For further NK cell analysis, CD3−CD5−CD56+ 
cells were gated within these cells using Cytobank, exported, and 
reanalyzed in Cytobank.
statistical analysis
For multiple group comparisons, one-way ANOVA or two-way 
ANOVA tests with Dunnett’s, Tukey’s, or Bonferroni’s multiple 
comparisons tests were applied. For single comparisons of 
matched groups, the paired Student’s t-test was performed. All 
figures present data as means ± SEM, ****p < 0.0001, ***p < 0.001, 
**p < 0.01, *p < 0.05, and ns = non-significant. Analyses were 
performed using Prism software (GraphPad).
resUlTs
cD161 expression Defines Two Distinct 
subsets of nK cells
Natural killer cells were defined as CD19−CD14−CD3−CD56+ 
cells in this study. CD161 expression divides peripheral blood 
NK  cells into two distinct populations in healthy adult donors 
(Figure  1A). Analysis of CD161 expression within cord blood 
samples, however, showed that NK cells were almost all CD161+ 
(Figures 1B,C), in line with previous reports (2). The frequency 
of CD161+NK  cells did not differ between 24-month-old and 
adult donors (Figure 1C), suggesting that the CD161− NK cells 
expand within the first 2 years of life. Dissection of NK cells into 
FigUre 1 | CD161 expression defines two distinct subsets of natural killer (NK) cells. (a) Gating strategy used to identify CD161+ and CD161− NK cells.  
(B) Representative staining showing the expression of CD161 in umbilical cord blood, 24-month olds (24mo), and adult individuals on total NK cells (CD3−CD56+ 
cells). (c) Frequencies of CD161+NK cells in cord blood (n = 5), 24-month olds (n = 28), and adult individuals (n = 33). (D) Representative staining showing the 
expression of CD161 on CD56bright and CD56dimNK cells in adult peripheral blood. (e) Frequencies of CD161+ cells within CD56bright and CD56dimNK cells (n = 33).
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the CD56bright and CD56dim NK cell populations (Figures 1D,E) 
showed that there is a substantial overlap between the popula-
tions, although there was a slight but significant enrichment of 
CD161+ cells within the CD56dim subset.
cD161+nK cells share high 
responsiveness to il-12 and il-18  
with cD161-expressing T cells
To further explore the CD161+NK  cell phenotype, mRNA 
microarray analysis was performed on FACS-sorted CD161+ 
and CD161− NK cell populations. Based on a cutoff of a twofold 
difference in transcript abundance and a p-value of less than 0.01, 
642 genes were identified as differentially regulated between the 
two subsets (Figure 2A; genes listed in Table S4 in Supplementary 
Material). Differential expression of some markers between the 
two subsets was confirmed at the protein level, and further phe-
notyping of receptors (Figure S2 in Supplementary Material) and 
cytotoxic molecules (data not shown) was performed, but none 
of the markers investigated were exclusive to CD161+ or CD161− 
NK cells. Moreover, there was no difference in surface CD107a 
expression after co-culture with K562 target cells between these 
populations (Figure S3H in Supplementary Material).
Recently, we have found that CD161 expression on T  cells 
identifies cells that share a core transcriptional signature, regard-
less of their lineage (25). Therefore, we investigated whether 
genes upregulated within CD161+NK cells were also shared with 
CD161-expressing T cells using GSEA (29). We tested whether 
the set of genes upregulated in peripheral CD8+T cells expressing 
CD161 at an intermediate level (CD161int) (28) compared to their 
FigUre 2 | CD161+NK cells share high responsiveness to IL-12+IL-18 with CD161-expressing T cells. (a) Heatmap illustrating significantly differentially 
expressed transcripts between CD161+ and CD161− NK cells in four donors. Subsets clustered by one minus Pearson correlation by GENE-E. (B) Gene set 
enrichment analysis of CD161+ vs. CD161− NK cells, showing a significant enrichment of genes upregulated in CD161+(intermediate) (CD161int) CD8+T cells compared 
to CD161−CD8+T cells (red = positively correlated, blue = negatively correlated) within CD161+ NK cells compared to CD161− NK cells. (c) Heatmap shows top 
17 genes that are highly (red) or lowly (blue) expressed in either CD161+ or CD161− NK cells. NES = normalized enrichment score. (D) IFNγ production by 
CD161+ and CD161− NK cells in response to overnight IL-12+IL-18 stimulation. N = 24. (e,F) gMFI of CD161 for CD161bright (++) (red), CD161int(+) (blue), and 
CD161− (green) subsets in CD8+T cells (e) or CD56dimNK cells (F), correlated with IFNγ expression in response to IL-12+IL-18 (n = 9). Representative staining 
showing IFNγ expression on indicated cells from the same donor, and gating of CD161bright (++), CD161int(+), and CD161− subsets based on CD8+T cells, are shown. 
(g) Representative staining showing IFNγ production in response to IL-12+IL-18 from CD57+ and CD57− cells within the CD56dim natural killer (NK) cell population 
(left). CD161bright (++), CD161int(+), and CD161− subsets were gated within CD57+ and CD57− NK cells as indicated. (h) Frequency of IFNγ+ cells in each population 
was graphed.
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CD161− counterparts was enriched significantly in either the 
CD161+ or CD161− NK cell population. There was a significant 
enrichment of genes upregulated in CD161int (28) in comparison 
to CD161−CD8+T  cells within CD161+NK  cells (normalized 
enrichment score = 2.46, p < 0.0001; Figures 2B,C). These genes 
included ZBTB16, which encodes the transcription factor PLZF 
that directs the innate-like effector functions of T  cells (32), 
and suggests that CD161+ NK cells and CD161int CD8+ T cells 
share a transcriptional signature. This was unique to CD161int 
CD8+ T  cells, as there was no significant enrichment of genes 
upregulated in CD161bright (++)CD8+ T cells, CD161+CD4+ T cells, 
or CD161+ γδ T  cells compared to their CD161− counterparts 
within CD161+ NK cells (data not shown).
We have previously found that CD161 expression on T cells 
identifies cells with the ability to respond to IL-12 and IL-18 
in a TCR-independent, “innate” manner (25). To investigate 
whether this functional correlate with CD161 expression 
extended beyond T  cells, IFNγ production in response to 
IL-12+IL-18 was assayed in CD161+ and CD161− NK  cells. 
This showed that although the majority of CD56bright NK cells 
secreted IFNγ regardless of CD161 expression, a consistently 
higher frequency of CD161-expressing CD56dim NK cells pro-
duced IFNγ compared to their CD161− NK cell counterparts 
(p <  0.0001) (Figure  2D). CD56 and CD161 expression was 
stable in most individuals tested after overnight stimulation, 
although there was a marginal increase in CD161 expression 
(Figures S3A,B in Supplementary Material). Furthermore, we 
have shown previously that the frequency of IFNγ-expressing 
cells correlates with the level of CD161 expressed when gat-
ing on CD161bright (++), CD161int(+), and CD161− CD8+ T  cells 
(Figure 2E). This correlation can also be seen in other T cells 
such as CD4+ T cells and γδ T cells (25). We found that gat-
ing on corresponding CD161-expressing populations in 
NK cells, IFNγ induction in response to IL-12 and IL-18 also 
strongly correlated with CD161 expression in CD56dimNK cells 
(Figure 2F) and the total CD56+ populations (Figure S3D in 
Supplementary Material), but not the CD56bright (Figure 
S3F in Supplementary Material). These results suggest that 
CD161 expression marks CD56dim cells with an increased 
ability to respond to IL-12 and IL-18, which is shared with 
CD161-expressing T cells. Presumably, this is due to the cor-
relation between CD161 and IL-18 receptor expression seen 
in the CD56dim (Figures S3E in Supplementary Material) 
and CD56bright populations (Figures S3G in Supplementary 
Material), although IL-18 receptor expression is already high 
on all CD56bright cells—explaining the lack of correlation 
between CD56 and IFNγ in this population. Of note, CD57 
expression has been shown to be a major determinant in the 
responsiveness of CD56dim NK cells to IL-12 and IL-18 (33, 34) 
and marks CMV-induced terminally differentiated NK  cells 
that have a reduced capacity to respond to IL-12 and IL-18 (17). 
However, gating on CD161bright (++), CD161int(+), and CD161− 
subsets within CD56dim NK cells showed that the frequency of 
IFNγ+ cells clearly increased with increasing CD161 expression 
within both CD57+ and CD57− CD56dim NK  cells, indicating 
that CD161 expression correlates with IL-12 and IL-18 respon-
siveness, independently of CD57 (Figures 2G,H).
cD161+ nK cells are highly Proliferative 
compared to cD161− nK cells
As CD161+ NK  cells had a significantly higher expression of 
the proliferative marker Ki67 at the gene level (Figure S3B in 
Supplementary Material), PBMCs were stimulated with differ-
ent combinations of cytokines or PHA for 5 days to compare 
the proliferative capacities of CD161+ and CD161− NK  cells. 
Strikingly, CD161+ NK  cells divided more extensively than 
CD161− NK  cells when stimulated with IL-2 or IL-15, either 
alone, together, or combined with IL-12, as well as PHA 
(Figures  3A,B). There was no significant difference in the 
expression of CD69 in response to IL-2, IL-15, IL-18, or PHA, 
suggesting that the reduced proliferation in CD161− NK cells 
is not due to their inability to respond to the cytokines. In 
all other conditions, expression of the activation marker 
CD69 was consistently higher in the CD161+ NK cell subset, 
reaching significance for all conditions with IL-12 or IL-15 
(Figure 3C). Furthermore, there was no significant difference 
in phosphatidylserine staining, a marker of apoptosis, between 
CD161+ and CD161− NK cells after culture with IL-2 or IL-15 
(Figure 3D), suggesting that the lower proliferative response of 
the CD161− NK cells was not due to higher rates of activation-
induced cell death in this subset. The higher proliferation 
observed from CD161+ NK  cells was also confirmed using 
FACS-sorted CD161+ and CD161− NK  cells (Figures  3E,F). 
Interestingly, proliferating NK  cells downregulated CD161 
expression with increasing rounds of division (Figure S4A in 
Supplementary Material). Together, these results suggest that 
CD161+ NK cells have a greater proliferative capacity compared 
to CD161− NK cells.
Of note, CD57 expression on NK  cells (33, 34) has been 
demonstrated to identify cells with low proliferative capacity. 
Analysis of CD161 and CD57 expression on NK cells proliferat-
ing following IL-15 stimulation for 5 days, however, showed that 
within both CD57− and CD57+ populations, the CD161+ NK cells 
showed greater dilution of the CTV dye (Figures  3G,H). This 
shows that CD161 expression correlates with the proliferative 
capacity of NK cells, independently of CD57.
cD161+ nK cells are enriched for cD103-
expressing cells in the inflamed gut
As CD161intCD8+ T  cells are enriched in the gut and express 
CD103 (28), an integrin associated with tissue-residency, we 
addressed whether CD161+ NK cells showed a similar association. 
Lamina propria lymphocytes were isolated from inflamed and 
non-inflamed areas of the small intestine from patients with IBD 
[mostly Crohn’s disease (CD)] and analyzed by mass cytometry. 
We found a significantly higher expression of CD103 on CD161+ 
compared to CD161− NK cells in the inflamed gut (Figure 4A), 
both among total NK  cells and CD56dim NK  cells (Figure  4B). 
CD103 expression was found to be at a lower frequency in healthy 
gut and tonsil, but not found on NK cells from the periphery. We 
also observed higher proportion of CD161+ NK cells expressing 
the tissue-residency markers CD103, CD69, and integrin-β7 
(Figure S5 in Supplementary Material) in the inflamed intestinal 
lamina propria of IBD patients.
FigUre 3 | Continued
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Thus CD161 expression marks NK cells that share transcrip-
tional and functional features with CD8+ T cells that also express 
CD161 and are enriched for CD103-expressing cells in the 
inflamed lamina propria.
high-Dimensional analysis Delineates  
nK cell Populations in cMV+ and  
cMV− Donors
Cytomegalovirus infection has been demonstrated to acceler-
ate the differentiation of NK cells, leading to the persistence 
of terminally differentiated NK cells expressing the activating 
heterodimer NKG2C/CD94 and CD57 (18, 35). Significant 
downregulation of CD161 on these cells has been reported 
(17, 20, 36). Confirming these findings, we found that CMV+ 
individuals had a significantly greater frequency of CD161− 
cells within their CD56dim NK  cell population (Figure  5A), 
but not CD56bright NK  cells (data not shown). Furthermore, 
there was a higher frequency of CD57+ and NKG2C+ cells 
(Figures 5B,C) within the CD161− CD56dim NK cell popula-
tion in CMV+ but not CMV− individuals, as expected (17, 
20, 36).
Peripheral blood mononuclear cells from CMV+ and CMV− 
adults, as well as cord blood samples, were stimulated with IL-12 
and IL-18 and the expression of 39 markers was simultaneously 
assessed by mass cytometry (Table S3 in Supplementary Material). 
t-SNE analysis (30, 37) of the expression of 36 parameters on 
live lymphocytes generated a two-dimensional composite map 
that clearly delineates cell subsets as distinct niches, or clusters 
(Figure 5D). NK cell clusters were further analyzed to generate 
a comprehensive overview of marker expression in each cluster. 
For the three NK cell clusters in one representative donor identi-
fied in Figure  5D, the median intensities of each marker was 
quantified and summarized using a heatmap illustration. This 
shows a clearly lower expression of NKp30, CD25, CD69, IFNγ, 
CD160, and to a lesser extent, CD161 and IL-18R in the CMV+ 
FigUre 3 | CD161+ natural killer (NK) cells have a greater proliferative capacity than CD161− NK cells. Peripheral blood mononuclear cells from healthy donors were 
CTV-labeled and cultured for 5 days with the indicated stimuli. (a) Representative staining of CellTrace Violet (CTV) for CD161+ and CD161− NK cells from one 
healthy donor. (B,c) Frequency of CD161+ and CD161− NK cells either (B) diluting CTV, or (c) expressing CD69, after simulation with the indicated combinations of 
cytokines and PHA (n = 14). Graphs show frequencies of CTVlow and CD69+ cells following background subtraction. (D) Frequency of CD161+ and CD161− NK cells 
expressing phosphatidylserine after 5 days culture with the indicated stimuli (n = 4). (e,F) CTV-labeled FACS-sorted CD161+ and CD161− NK cells were stimulated 
with IL-15 for 5 days or left unstimulated, and the frequency of cells diluting CTV (CTVlow) was analyzed (n = 3). (e) Representative staining and (F) frequency data 
are shown. (g) Representative staining for CTV on CD57+ and CD57− NK cells, according to CD161 expression. (h) Frequency of cells diluting CTV on indicated 
CD56dim NK cell subsets stimulated with IL-15, according to CD161 and CD57 expression (n = 3). CD56brightNK cells were excluded as they do not express CD57.
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donor-specific NK3 cluster, while they expressed higher levels of 
NKG2C, CD57, and CD16.
t-Distributed stochastic neighbor embedding analysis of 
the expression of these parameters on NK cells from all donors 
identified five distinct clusters (Figure S6 in Supplementary 
Material). Interestingly, two of these NK cell clusters were high 
in NKG2C expression (clusters 1 and 2), and while one of these 
NKG2C+CD161−IFNγ− clusters (cluster 1) was only present in 
CMV+ individuals, cluster 2 was present in CMV− adults but not 
cord blood, suggesting that CMV may induce the expansion of these 
NKG2C+CD161−IFNγ− cells (cluster 2), which further differenti-
ates into cluster 1. Thus, CD161 expression marks CD56dimNK cells 
that have retained their responsiveness to innate cytokines; an 
ability that is lost upon CMV-induced terminal differentiation.
cD161+ nK cells are Depleted  
in cMV-seropositive hiV Donors  
and recover with arT
We next wanted to investigate whether CD161 expression 
changes in other viral diseases. CD161 expression on NK cells 
has been reported to be reduced in the periphery of chronic HIV 
patients (13, 38, 39). To investigate whether this subset recovers 
in patients receiving ART, the frequency of CD161+ NK cells in 
27 patients with chronic HIV infection from the SHCS were fol-
lowed for 2 years of ART. Samples were taken prior to the start of 
treatment (T-0), at 1 year (T-1), and 2 years (T-2) into treatment 
and analyzed by flow cytometry in a blinded manner.
Previous findings that the frequency of CD161+ NK  cells 
were dramatically lower in HIV patients was initially con-
firmed by comparing the frequency of CD161+ NK  cells in 
these HIV patients to that in healthy controls (Figure S7 in 
Supplementary Material). However, our initial comparison did 
not take into account the CMV seropositivity of the “healthy” 
controls. CMV infection and reactivation is common in immu-
nosuppressed HIV patients (40, 41), and indeed 25 out of 27 
patients were CMV seropositive in the SHCS cohort. In order 
to control for the expansion of the CD161− NK cells that occurs 
in CMV+ donors, the frequency of CD161+ NK cells in CMV+ 
HIV patients and CMV+ healthy donors were compared. We 
found that within total NK  cells (Figure  5E) and CD56dim 
NK cells (Figure 5F), there was a significantly lower frequency 
FigUre 4 | CD161+ NK cells are enriched for CD103-expressing cells in the inflamed gut. (a,B) FACS plots (a) and bar graph (B) showing CD103 expression on 
indicated natural killer (NK) cell populations isolated from the periphery (n = 5), tonsil (n = 1), or the lamina propria, either inflamed from IBD patients (n = 7) or 
non-inflamed lamina propria (n = 4) as analyzed by mass cytometry. FACS plots gated on total CD3−CD56+ NK cells. IBD, inflammatory bowel disease.
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of cells expressing CD161 in CMV+ HIV patients, compared 
to healthy CMV− donors, but not compared to healthy CMV+ 
donors. There was no significant difference in CD161 expres-
sion in CD56bright NK  cells between healthy donors and HIV 
patients, regardless of CMV status (Figure 5G). This suggests 
that CD161 downregulation on NK  cells in HIV patients 
may be associated with their CMV seropositive status, due 
to the lower expression of CD161 on CD56dim NK  cells in 
CMV+ individuals. Indeed, the two CMV seronegative HIV 
patients had a high expression of CD161, with 83 and 87.8% of 
CD56dimNK cells expressing CD161, respectively, compared to 
a mean of 61.90 ± 3.84% of CD56dimNK cells from CMV+ HIV 
patients expressing CD161.
Next, we investigated whether CD161 expression recovers 
with successful ART treatment. Surprisingly, a comparison of 
CD161 expression in total, CD56dim, and CD56bright NK  cells 
(Figures  5H–J) showed that in all populations, there was a 
significant increase in the frequency of cells expressing CD161 
with treatment (T-0 vs. T-2; Figures 5K,L). Interestingly, there 
was a small but significant correlation between CD4 counts 
and frequency of cells expressing CD161 in both CD56bright and 
CD56dimNK cells (Figures S7C,D in Supplementary Material) in 
these patients after, but not before, 2 years of ART treatment.
DiscUssiOn
In this study, the transcriptional signature and functional capac-
ity of human CD161+ and CD161− NK  cells was investigated. 
We show that CD161 marks cytokine-responsive NK  cells, 
independently of CD57 or CMV status, sharing transcriptional 
and functional features with T  cells expressing CD161. These 
findings are important given the recent observation that CD161 
was the best prognostic marker expressed by tumor-associated 
leukocytes across 39 different malignancies (42). Furthermore, 
in contrast to “adaptive” NK cells, which are highly responsive 
to antibody-opsonized target cells but not to cytokines or tumor 
target cells (17), these pro-inflammatory, “innate” NK cells have 
the potential to play a role in the inflamed gut.
CD161 is expressed early in NK  cell development, where it 
may facilitate cross-talk of NK cell precursors with cells within 
the bone marrow, and is involved in CXC8 release (6–8). Within 
the periphery, cross-linking of CD161 leads to an increase in 
IFNγ expression and inhibition of NK  cell (43–47). In this 
study, under certain stimulatory conditions, CD161 expression 
decreases with proliferation (Figure S4A in Supplementary 
Material); raising the question if CD161- NK are derived from 
highly activated NK cells. However, a complete loss of CD161 was 
not observed, even on those cells that had under gone the greatest 
rounds of proliferation, suggesting that additional factors would 
be required.
The most striking functional difference between CD161+ 
and CD161− NK  cells was their capacity to respond to pro-
inflammatory cytokines, particularly within CD56dim NK  cells. 
Thus, CD161 identifies NK  cells that have retained the ability 
to respond to IL-12 and IL-18 during differentiation, expressing 
highest levels of IFNγ, NKp30, CD160, CD25 (part of the high-
affinity IL-2 receptor) and CD69 following stimulation. This is 
in line with recent studies showing that reduced expression of 
the transcription factor promyelocytic leukemia zinc finger 
(PLZF) in NKG2C+CD57++ “adaptive” NK  cells in CMV leads 
FigUre 5 | Continued
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to downregulation of CD161, IL-12R and IL-18R in these cells 
(17, 48). Here we have found using multidimensional analysis that 
this functional association between CD161 and IL-12 and IL-18 
responsiveness was preserved in both CMV+ donors and CMV− 
donors, and this functional correlation was also independent of 
CD57 expression that marks mature NK cells (33). Thus, CD161 
FigUre 5 | Changes in CD161 expression in cytomegalovirus (CMV) and human immunodeficiency virus (HIV) infection. (a) Frequencies of CD161− NK cells  
within the CD56dim natural killer (NK) cell population within CMV+ (n = 16) and CMV− (n = 16) individuals. Data combined from four independent experiments.  
(B,c) Frequencies of (B) CD57+ cells or (c) NKG2C+ cells in CD161+ or CD161 population of CD56dim NK cells, in CMV+ and CMV− donors. N = 14 for CMV+, 
n = 11 for CMV− individuals. (D) Peripheral and cord blood samples were stimulated with IL-12+IL-18 overnight and acquired by mass cytometry. (h) t-distributed 
stochastic neighbor embedding analysis was performed on CMV+ (n = 5) and CMV− donors (n = 6). The median intensities of each marker were calculated for the 
NK cell populations identified (left) and plotted as a heatmap (right). (e–l) The frequency of CD161-expressing NK cells in patients with chronic-stage HIV infection 
from the Swiss HIV cohort study, who were followed for 2 years of anti-retroviral therapy (ART), with samples taken prior to the start of the treatment (T-0), at 1 year 
(T-1), and 2 years (T-2) into treatment. Patients were tested for CMV seropositivity prior to the start of treatment (n = 27, Table S2 in Supplementary Material). The 
frequency of CD161+ NK cells within (e) total NK cells (CD3−CD56+), (F) CD56dim NK cells, and (g) CD56bright NK cells is shown for HIV patients at T-0 (n = 25 for 
CMV+, n = 2 for CMV−), compared to CMV+ (n = 16) and CMV− (n = 16) healthy donors. (h–J) Frequency of CD161+ NK cells within HIV patients followed  
for 2 years of ART. CD161+ cells within (h) total NK cells, (i) CD56dim NK cells, and (J) CD56bright NK cells are shown for HIV patients at T-0, T-1, and T-2.  
(K) Representative staining showing CD161 expression on total NK cells from one patient at T-0 (left), T-1 (center), and T-2 (right). (l) Histogram overlaying  
CD161 expression on total NK cells from one patient.
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is a marker of pro-inflammatory NK cell function, independent 
of CMV-induced differentiation.
Whether NK  cells lose CD161 in a linear fashion as they 
mature is unclear. All NK cells expressed CD161 at a high level in 
cord blood, but a distinct CD161− NK population was present in 
24-month-old samples, suggesting that CD161− NK cells expand 
early in life. Interestingly, not all the properties of CD161+ 
NK cells are consistent with these cells being more immature than 
the CD161− NK cells. For instance, CD161− cells are present in 
the CD56bright NK cell population which are considered to be 
more immature than CD56dim NK cells, and there was no differ-
ence in CD57 expression between CD161+ and CD161− cells in 
CMV-negative donors. Instead CD161 expression may be linked 
with education which is disassociated from NK cell maturation 
(34). CD161 ligation has been shown to inhibit NK cell cytotoxic-
ity (4, 5). The downmodulation of the inhibitory molecule CD161 
may enhance the ability of NK cells to kill infected or transformed 
cells, but would also result in unchecked cytotoxicity that could 
be harmful to “self.” As NK  cells are licensed through ligation 
of KIRs by self-specific HLA ligands (49, 50) it is tempting to 
speculate that downregulation of CD161 may be associated with 
increased education and expression of other inhibitory recep-
tors that recognize classical MHC class I molecules. Indeed, 
NKG2C+CD57+ cells have clonal expression pattern of inhibitory 
KIRs specific for self-HLA class I molecules (20, 43). A popula-
tion of NKG2C-negative NK cells expressing inhibitory self-KIRs 
can also expand in CMV+ individuals (43–45). As CMV induces 
the downregulation of MHC class I molecules, except for HLA-E, 
cells expressing inhibitory self-KIRs and NKG2C (which binds 
HLA-E) may selectively expand (44). Alternatively, as CD161 
expression is controlled by the chromatin modifying transcrip-
tion factor PLZF (17, 51), its expression may be linked to factors 
other than maturation such as epigenetic modification.
Previous studies have shown that, in the context of HCMV, 
IL-15-induced NK  cell proliferation is dependent on receptor 
signaling, in particular through NKG2C (52). We confirm these 
findings and show that this is restricted to the CD161- popula-
tion (n = 1, Figure S4C in Supplementary Material). Interestingly, 
cytokine-induced memory-like NK  cells can be induced by 
pre-activation with IL-12, IL-15, and IL-18 (53), cytokines that 
CD161+ NK cells are most responsive to. These cytokines induce 
the upregulation of CD25, which allows these cells to respond to 
IL-2 produced by memory T cells. Whether these memory-like 
NK  cells are indeed derived from CD161+ NK  cells, perhaps 
following cytokine-induced expansion and downregulation of 
CD161 (Figure S4A in Supplementary Material) requires further 
investigation. This would be important in understanding the 
pathway leading to the generation of memory and provide a 
useful marker in the ongoing therapeutic application of cytokine-
induced memory-like NK cells in hematologic malignancies (53).
We observed a higher proportion of CD161+ NK cells express-
ing the tissue-residency markers CD103, CD69, and integrin-β7 
(Figure S5 in Supplementary Material) in the inflamed intestinal 
lamina propria of IBD patients. This is reminiscent of the 
increased frequency of CD103+ intraepithelial (ie)ILC1 cells in 
the epithelia of CD patients (54). Interestingly these cells have 
recently been redefined as NK cells that reside in mucosal and 
non-mucosal pathological tissues (55). Indeed, consistent with 
Simoni and colleagues’ findings, the CD103+ NK  cells identi-
fied in our study expressed CD56, CD94, Eomes, perforin, and 
lacked NKp44 or CD127 expression (Figure S5 in Supplementary 
Material). These ieILC1-like cells are enriched within the CD161+ 
NK cell population in the lamina propria of IBD patients. Given 
the increased presence of ieILC1-like cells in inflamed intestinal 
tissues, as well as non-mucosal pathological tissues (e.g., tumors), 
the CD161+ subset of these cells may contribute to disease patho-
genesis because of their ability to respond to the abundant IL-12 
and IL-18 that characterizes CD and secrete IFNγ (56). Indeed, 
IFNγ-producing ieILC1 cells have been shown to contribute to 
the development of colitis in a murine model of IBD (54).
In the present study of HIV-infected patients, CD161 expres-
sion in CD56dim NK  cells was significantly reduced compared 
to healthy CMV− donors, but not compared to healthy CMV+ 
donors. Although only two HIV patients were CMV seronegative, 
both donors had high expression of CD161, which did not change 
with ART (data not shown). Therefore, CD161 downregulation 
may be associated with CMV reactivation or re-infection due to 
progressive immunodeficiency during HIV infection, as has been 
demonstrated for increased NKG2C expression in HIV patients 
(57, 58). The loss of the CD161+ NK cell subset in HIV-infected 
patients may potentially lead to cells having a reduced proliferative 
capacity in response to homeostatic cytokines as well as a reduced 
capacity to secrete IFNγ in response to innate cytokines (59). 
Prior infection with CMV is a risk factor for a low CD4 count, 
progression to AIDS and mortality in HIV patients (40). Whether 
CMV-driven differentiation, and possibly exhaustion, of NK cells 
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reduces their ability to mediate HIV control will be important to 
investigate, given recent evidence of their role in elite controllers 
(60) and reducing the size of the viral reservoir (61).
In summary, we have shown that CD161 is a marker of 
NK  cell function, particularly marking pro-inflammatory 
NK  cells, which is expressed on all NK  cells in cord blood, 
downregulated upon proliferation, and lost upon CMV-induced 
terminal differentiation. CD161 expression on CD56dim NK cells 
marks cells that have retained the capacity to respond to inflam-
matory cytokines alone. CD161, thus, identifies “innate” cells 
within both NK cells and CD161bright T cell family, previously 
described, with shared innate-type responses that are independ-
ent of receptorligation (25).
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